Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250021, China; Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.
Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250021, China; Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.
Int Immunopharmacol. 2021 May;94:107504. doi: 10.1016/j.intimp.2021.107504. Epub 2021 Feb 28.
As an attractive tumor-associated antigen (TAA), Wilms tumor gene 1 (WT1) is usually overexpressed in malignant hematological diseases. In recent years, WT1-specific adoptive immunotherapy has been the "hot spot" for tumor treatment. The main immunotherapeutic techniques associated with WT1 include WT1-specific cytotoxic T lymphocytes (CTLs), vaccine, and T cell receptor (TCR) gene therapy. WT1-based adoptive immunotherapy exhibited promising anti-tumorous effect with tolerable safety. There are still many limitations needed to be improved including the weak immunogenetics of WT1, immune tolerance, and short persistence of the immune response. In this review, we summarized the progress of productive technologies and the clinical or preclinical investigations of WT1-specific immunotherapy in hematological diseases.
作为一种有吸引力的肿瘤相关抗原（TAA），Wilms 肿瘤基因 1（WT1）通常在恶性血液病中过度表达。近年来，WT1 特异性过继免疫治疗已成为肿瘤治疗的“热点”。与 WT1 相关的主要免疫治疗技术包括 WT1 特异性细胞毒性 T 淋巴细胞（CTLs）、疫苗和 T 细胞受体（TCR）基因治疗。基于 WT1 的过继免疫治疗表现出有希望的抗肿瘤效果，且安全性可耐受。仍有许多需要改进的局限性，包括 WT1 的免疫遗传学较弱、免疫耐受和免疫反应的持续时间短。在这篇综述中，我们总结了 WT1 特异性免疫治疗在血液系统疾病中的有成效的技术进展和临床前或临床研究。
